doi: 10.3389/fphar.2026.1769333 Received 16 December 2025 Revised 09 April 2026 Accepted 20 April 2026 Published 21 May 2026 Volume 17 - 2026 Edited by Alasdair Barr, University of British Columbia, Canada Reviewed by Ze-Ka Chen, University of North Carolina at Chapel Hill, United States Judy Van Stralen, JPM van Stralen Medicine Professional Corporation, Canada Updates Copyright 2026 Young, Powell, Powell, Welling, Granata, Saal, Nash and Corliss
The FDA does not review or approve compounded medications for safety or effectiveness
Likewise, for the peripheral tissue -synuclein, the variations in immunohistochemical techniques and the lack of knowledge on different forms of -synuclein present in the tissue in normal and pathological conditions and the limited number of commercially available antibodies are the major concerns
The second arm of the neuroprotective action of CBD is related to the hypoxia-inducible factor-1 alpha (HIF-1)
Moreover, tirzepatide led to significant improvements in HbA1c and other CV metabolic risk factors [92]
Related Content KRAS G12D inhibitors continue to advance, but treatment resistance remains an important challenge